To sell a natural health product (NHP) in Canada, companies must consider both product licensing and site licensing requirements. A product licence authorizes the sale of a specific NHP, while a site licence is required for the Canadian physical site where NHPs are manufactured, packaged, labelled, or imported for sale.
Obtaining these licences requires regulated parties to demonstrate that the product meets applicable safety, efficacy, and quality requirements, and that licensable site activities are conducted in accordance with the good manufacturing practices (GMP) requirements set out in the Natural Health Products Regulations. Health Canada requires Canadian sites that manufacture, package, label, or import NHPs for sale to hold a valid site licence and comply with applicable GMP requirements.
However, regulatory responsibility does not end once the licences are issued. NHP site licence holders must maintain compliance, renew their site licences, and be prepared for Health Canada inspections that assess whether licensed activities are appropriately controlled and supported by GMP evidence.
This article provides a high-level overview of key considerations for NHP site licence holders preparing for a Health Canada inspection. Because requirements can vary by product type, site activity, and quality system, companies should seek professional guidance where needed.
If your team is preparing for inspection or strengthening ongoing GMP readiness, SNI can support quality assurance (QA), site licensing, documentation, and strategic NHP compliance.
- Understanding the Basics of NHP Site Inspections
- What Is a Health Canada NHP Site Licence Inspection?
- Preparing for an NHP Site Licence Inspection
- Confirm That the Site Licence Reflects Current Activities
- Understand the Applicable Regulatory Framework
- Resources for NHP Site Inspection Preparation
- Conduct an Internal GMP Readiness Assessment
- Prepare Inspection Records in Advance
- Ensure Personnel Understand Their Responsibilities
- Review Premises, Equipment, Sanitation, and Storage Controls
- Strengthen Supplier and Foreign Site Controls
- Review Product Specifications and Release Documentation
- Review Complaints, Recalls, Deviations, and CAPA
- Understanding and Responding to Health Canada Inspection Observations
- Maintaining Inspection Readiness After the Inspection
- Final Remarks
- FAQ
Understanding the Basics of NHP Site Inspections
The Purpose of a Site Inspection
A Health Canada NHP site inspection focuses on whether the activities conducted under a site licence are controlled and compliant with applicable GMP requirements. Inspections are performed by Health Canada inspectors as part of the department’s compliance and enforcement oversight.
When Site Inspections Are Conducted
Inspections may be performed as part of routine compliance monitoring, in response to a compliance concern, following quality issues such as complaints or recalls, or when Health Canada needs to verify continued compliance. They are not limited to the initial licensing stage and should be treated as part of ongoing site licence maintenance.
Objective for NHP Site Licence Holders
For NHP site licence holders, the objective is to demonstrate that operations remain aligned with the site licence and that GMP controls are consistently maintained. This makes inspection readiness an ongoing compliance obligation, not a one-time activity triggered by inspection notice.
What Is a Health Canada NHP Site Licence Inspection?
A Health Canada NHP site licence inspection is a regulatory assessment of whether a site conducting licensable NHP activities is complying with applicable GMP requirements in Canada.
These inspections apply to parties that manufacture, package, label, or import NHPs for sale. In practice, Health Canada is assessing whether the site can demonstrate that its licensed activities are controlled, documented, and supported by appropriate quality system evidence.
What Is Reviewed During an NHP Site Licence Inspection?
The inspection may include a review of the following areas:
Site Operations
Health Canada may assess how licensed activities are conducted, including whether day-to-day operations align with the site licence and applicable procedures.
Quality System
Inspectors may review the overall quality system to confirm that responsibilities, controls, approvals, investigations, and oversight processes are clearly defined and implemented.
Procedures
SOPs may be reviewed to determine whether they are current, approved, and reflective of actual site practices.
Personnel Training
Training records may be assessed to confirm that personnel are qualified for their assigned responsibilities and trained on applicable GMP procedures.
Records
Health Canada may review whether records are complete, accurate, current, attributable, and readily retrievable during inspection.
Premises
The site may be assessed to confirm that the facility supports appropriate material flow, storage, segregation, sanitation, and prevention of contamination or mix-ups.
Equipment
Equipment may be reviewed to confirm that it is suitable for its intended use and supported by appropriate maintenance, cleaning, and calibration records.
Sanitation Practices
Inspectors may assess whether sanitation procedures are documented, implemented, and sufficient to maintain appropriate conditions for NHP activities.
Supplier Controls
Supplier qualification files, foreign site evidence, and quality agreements may be reviewed to confirm that suppliers are appropriately assessed and monitored.
Complaints
Complaint files may be reviewed to determine whether complaints are documented, investigated, assessed for product impact, and escalated where required.
Recalls
Recall procedures and records may be assessed to confirm that the site can trace affected products and take timely action when required.
Deviations
Deviation records may be reviewed to confirm that non-conformances are documented, investigated, assessed for impact, and appropriately closed.
Corrective and Preventive Actions (CAPA)
CAPA records may be assessed to determine whether root causes are identified, corrective actions are implemented, and effectiveness is verified.
Product Release Decisions
Release records may be reviewed to confirm that products are assessed against applicable specifications and approved by qualified personnel before sale.
Preparing for an NHP Site Licence Inspection
Preparation for a site licence inspection should begin when the site’s processes and activities are first developed, rather than once an inspection is scheduled. Building GMP expectations into procedures from the outset helps ensure that daily operations remain aligned with the Natural Health Products Regulations and the conditions of the site licence.
In practice, inspection readiness is supported by consistent day-to-day execution. Procedures should be accurate, followed as written, and supported by complete records that show what was done, who was responsible, and how quality decisions were made.
For site licence holders, this means inspection preparation should be treated as part of routine quality and operational decision-making. The following sections outline key areas to consider when assessing readiness for a Health Canada NHP site licence inspection.
Confirm That the Site Licence Reflects Current Activities
Before an inspection, companies should confirm that the site licence accurately reflects the activities currently conducted at the establishment.
This review should consider the licensed activities, site address, applicable products, foreign sites or suppliers, quality personnel, and any operational changes since the licence was issued or last amended.
This is particularly important where a company’s activities have expanded, such as moving from importing only to applying bilingual labels, relabelling, changing storage arrangements, or taking on additional release responsibilities.
Where operations have evolved, companies should assess whether the site licence scope, GMP procedures, or supporting records need to be updated before inspection.
Understand the Applicable Regulatory Framework
Companies should review and understand the applicable site licensing guidance, the NHP GMP guide, and the NHP GMP pre-inspection package before an inspection. This is particularly important with GUI-0158 Version 4.0, which was published on September 4, 2025, and took effect on March 4, 2026.
Processes that were developed under previous guidance may no longer fully reflect Health Canada’s current expectations. Companies should therefore confirm that their documentation, procedures, quality system controls, and operational practices remain aligned with the most recent requirements.
Ideally, site licence holders should have a defined process for monitoring regulatory updates, assessing their impact, and implementing required changes. Assigning clear responsibility for this process helps ensure that GMP controls remain current and inspection-ready.
Aligning preparation with the most current guidance helps ensure that inspection records, procedures, and quality system controls reflect Health Canada’s current expectations.
Resources for NHP Site Inspection Preparation
Health Canada’s updated GMP guide, GUI-0158, is intended to help organizations understand and comply with Part 3 of the Natural Health Products Regulations. The guide applies to persons and companies involved in NHP-related activities or roles, including manufacturing, packaging, labelling, importing, distributing, storing, testing, and holding a product licence.
In practice, an inspection evaluates whether the site can demonstrate that NHPs are consistently handled under conditions that support product quality, safety, and traceability.
Conduct an Internal GMP Readiness Assessment
Companies should conduct an internal GMP readiness assessment before receiving inspection notice. The assessment should be practical, documented, and focused on whether the site can demonstrate control over its licensed activities.
At a high level, the review should confirm that procedures are current and implemented, personnel are trained for their responsibilities, and key records are complete, accurate, and readily retrievable. It should also assess whether quality decisions, including product release, deviations, complaints, and CAPA, are supported by appropriate evidence.
The objective of the internal GMP readiness assessment is to determine whether the quality system is functioning as intended and whether the site can show that activities are performed in accordance with approved procedures and GMP expectations.
Prepare Inspection Records in Advance
Health Canada inspections may include requests for records before or during the inspection. To support an efficient process, companies should maintain a current and organized inspection file that allows key documents to be retrieved and presented when requested.
This file should include:
- Core site licence records
- Quality system documents
- Personnel and training records
- Product and activity information
- Supplier or contractor documentation
- Internal audit records
- CAPA and complaint logs
- Batch and release records
- Records that support premises, equipment, sanitation, pest control, and storage controls
The inspection file should be controlled and kept up to date. It should not replace the quality system, but it should help demonstrate that relevant records are accessible, organized, and aligned with the site’s licensed activities.
Where electronic records are used, companies should ensure that records are controlled, readily retrievable, protected from unauthorized changes, and maintained in accordance with applicable record retention requirements.
Ensure Personnel Understand Their Responsibilities
In preparation for an NHP site inspection, companies should also ensure that personnel are prepared to speak to their assigned responsibilities. Staff should be able to describe the activities they perform, identify the procedures that apply, and explain the records they are responsible for completing.
During an inspection, Health Canada may assess whether roles and responsibilities are clearly defined, understood by personnel, and implemented consistently in practice. The following should be considered:
- Personnel should provide responses that reflect actual practices. They should be able to identify the applicable procedure, explain how required records are maintained, and understand when issues must be escalated to QA.
- QA personnel should be prepared to explain how quality-related activities are managed. Health Canada may also consider the effectiveness of the QA function, including whether QA personnel have the knowledge, training, and independence needed to support GMP compliance.
- For importers, this should also include an understanding of how foreign site evidence is reviewed and how product acceptability is assessed before release in Canada.
Review Premises, Equipment, Sanitation, and Storage Controls
The physical site should be suitable for the activities conducted and maintained in a way that supports material flow, segregation, sanitation, storage, and prevention of contamination or mix-ups.
Licence holders should verify that materials are clearly identified and appropriately segregated, including quarantine, approved, rejected, returned, and recalled materials. Printed packaging and labels should also be controlled to prevent mix-ups, and storage conditions should be monitored where they may affect product quality or stability.
Equipment should be suitable for its intended use and supported by appropriate cleaning, maintenance, and calibration records. Sanitation and pest control programs should be current, documented, and implemented in accordance with approved procedures.
During the premises tour, Health Canada may compare observed site conditions against written procedures and records. Any inconsistency between documented controls and actual practice may result in an inspection observation.
Strengthen Supplier and Foreign Site Controls
For NHP importers, supplier and foreign site controls should be maintained in a manner that supports the quality and acceptability of products imported for sale in Canada. The importer should be able to demonstrate that foreign site documentation is reviewed, supplier status is maintained, and imported lots are assessed before release.
This may include applicable supplier qualification records, foreign site GMP evidence, quality agreements, specifications, certificates of analysis, release documentation, and procedures for managing quality issues. Where concerns are identified, the importer should document the assessment, escalation, and any required follow-up.
Although certain activities may occur outside Canada, the Canadian importer remains responsible for maintaining appropriate oversight of the products it imports. Weak or insufficient oversight of foreign sites, suppliers, or GMP evidence may compromise the Canadian site’s compliance position and, where significant deficiencies are identified, may contribute to regulatory action, including site licence suspension.
Review Product Specifications and Release Documentation
Product specifications should be current, approved, and appropriate for the product. They should support the assessment of relevant quality parameters, including identity, purity, quantity, potency, and other applicable characteristics.
Before inspection, companies should review specifications, certificates of analysis (COAs), testing records, and release documentation to confirm that the basis for release is clearly documented. Release decisions should be made by qualified personnel before the product is made available for sale.
Where deviations, out-of-specification (OOS) results, complaints, supplier concerns, or stability issues are identified, the potential impact on product release should be assessed and recorded. Release records should show what was reviewed, who approved the release, and why the lot was considered acceptable.
Review Complaints, Recalls, Deviations, and CAPA
Complaint, recall, deviation, and CAPA records should demonstrate that quality issues are documented, assessed, investigated, and addressed in a timely and appropriate manner.
Complaint files should show how the issue was received, assessed, investigated, and closed, including any product impact assessment. Recall procedures should be current and should support product traceability, defined responsibilities, communication, and effectiveness checks.
Deviation and CAPA records should identify the issue, assess potential impact, determine root cause, define CAPA, assign responsibility, and verify effectiveness. Recurring issues should be trended and escalated through the quality system where appropriate.
Understanding and Responding to Health Canada Inspection Observations
Reviewing Observations and Inspection Outcomes
During an inspection, Health Canada may identify observations where the site does not appear to meet applicable GMP requirements. These observations should be reviewed carefully, assigned appropriate internal follow-up, and assessed for potential impact on product quality, consumer safety, and site licence compliance.
Following an NHP GMP inspection, Health Canada may assign observations a risk category and issue an overall compliance rating of compliant or non-compliant. Where significant deficiencies are identified, the inspection outcome may inform Health Canada’s site licensing decisions or other regulatory actions.
Developing a CAPA Response
A strong response should be documented through the CAPA process and include, where applicable:
- Immediate containment
- Product impact assessment
- Root cause analysis
- CAPA
- Responsible owners and target completion dates
- Objective evidence of completion
- Effectiveness checks
The response should be specific, evidence-based, and proportionate to the observation. Updating a procedure may be appropriate, but it is often not sufficient on its own. Companies may also need to demonstrate that personnel were trained, affected records were reviewed, supplier controls were strengthened, product impact was assessed, or broader system-level improvements were implemented.
Assessing Broader Quality System Impact
Where observations identify a potential quality system weakness, companies should assess whether other products, records, sites, suppliers, or activities may also be affected. This helps ensure the response addresses the underlying issue and not only the individual inspection finding.
Maintaining Inspection Readiness After the Inspection
Track Observations and CAPA Commitments to Closure
Inspection readiness should continue after the inspection is complete. Companies should track all observations, commitments, corrective actions, and preventive actions through to closure, with clear owners, timelines, and supporting evidence.
CAPA effectiveness should also be verified. This helps demonstrate that the company did not only respond to the inspection finding, but also assessed whether the action taken was sufficient to prevent recurrence.
Integrate Inspection Outcomes into the Quality System
Management should review the status of open actions regularly. If an observation identifies a broader system weakness, the company should assess whether other products, sites, suppliers, records, procedures, or activities may also be affected.
Inspection outcomes should be incorporated into the internal audit program, management review process, training program, and continuous improvement activities. This helps ensure that inspection preparation
Final Remarks
Preparing for a Health Canada NHP site licence inspection requires more than assembling documents before the inspection begins. Companies must be able to demonstrate that their licensed activities are accurate, controlled, and supported by current records.
A well-prepared site should be able to show that procedures are implemented, personnel are trained, product quality decisions are justified, supplier and foreign site controls are maintained, and complaints, recalls, deviations, and CAPA are managed through a functioning quality system.
For NHP manufacturers, packagers, labellers, and importers, inspection readiness is an essential part of maintaining site licence compliance in Canada. The most effective approach is to build readiness into day-to-day operations so that, when Health Canada requests evidence, the site can provide it clearly, consistently, and without relying on last-minute reconstruction.
Need Help Preparing for a Health Canada NHP Site Licence Inspection?
Preparing for a Health Canada NHP site licence inspection requires more than organizing documents before the inspection date. Site licence holders must be able to demonstrate that licensed activities are controlled, procedures are implemented, records are complete, and GMP expectations are built into day-to-day operations.
SNI supports NHP companies with site licensing, GMP readiness, QA review, supplier and foreign site documentation, inspection preparation, CAPA strategy, and ongoing compliance support. Whether your team is preparing for an upcoming inspection, responding to observations, or strengthening long-term GMP controls, SNI can help align your site activities, documentation, and quality system with Health Canada expectations.
FAQ
What is a Health Canada NHP site licence inspection?
A Health Canada NHP site licence inspection is a regulatory assessment of whether a site conducting licensable NHP activities is complying with applicable GMP requirements in Canada. These inspections may apply to sites that manufacture, package, label, or import NHPs for sale and are used to assess whether licensed activities are controlled, documented, and supported by appropriate quality system evidence.
Who needs to prepare for an NHP site licence inspection in Canada?
Companies that manufacture, package, label, or import NHPs for sale in Canada should maintain inspection readiness. This includes site licence holders, importers, QA teams, manufacturers, packagers, labellers, and any personnel responsible for records, product release, supplier qualification, complaints, recalls, deviations, or CAPA.
What does Health Canada review during an NHP site licence inspection?
Health Canada may review the site’s operations, quality system, procedures, training records, premises, equipment, sanitation controls, supplier documentation, product specifications, batch and release records, complaints, recalls, deviations, CAPA, and other records that demonstrate GMP compliance. Inspectors may also assess whether written procedures are implemented consistently in practice.
How should companies prepare for a Health Canada NHP site licence inspection?
Companies should confirm that the site licence reflects current activities, review applicable Health Canada guidance, conduct an internal GMP readiness assessment, organize inspection records, prepare personnel to explain their responsibilities, and verify that key quality system controls are current and implemented. Preparation should be part of routine GMP operations rather than a last-minute activity before inspection.
What happens if Health Canada identifies observations during an NHP inspection?
If Health Canada identifies inspection observations, the company should assess the potential impact on product quality, consumer safety, and site licence compliance. Observations should be addressed through a documented CAPA process that includes appropriate containment, root cause analysis, CAPA, assigned responsibilities, timelines, supporting evidence, and effectiveness checks.
The content on this website, including information presented in this post, is provided for general informational purposes only and does not constitute legal, regulatory, or professional advice. While efforts are made to ensure accuracy, laws and regulations vary by jurisdiction and may change over time. Readers should not rely on this information as a substitute for advice from qualified legal or regulatory professionals. We disclaim any liability for actions taken based on this content, and users are encouraged to seek guidance specific to their circumstances.
